Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).
Sophie GodetCaroline ProtinJehan DupuisCaroline DartigeasJean-Noël BastieCharles HerbauxVéronique LeblondSophie de GuibertDavid GhezAnnie BrionLoic YsebaertAlain DelmerAnne QuinquenelPublished in: American journal of hematology (2017)